Solage

Quick links to important sections

Solage

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solage

Quick Facts

  • Active Ingredients: Mequinol (2%) and Tretinoin (0.01%)
  • Dosage Form: Topical Solution
  • Indication: Treatment of solar lentigines (age or liver spots)

Solagé (mequinol and tretinoin) Topical Solution is a prescription-only medication for the treatment of solar lentigines, commonly referred to as age or liver spots. Solar lentigines are localized, pigmented skin lesions that result from chronic sun exposure, often appearing as areas that have become darker over time.

This medication is a combination product intended for topical, or on-the-skin, use only. Its application is meant to be an adjunct to a comprehensive sun avoidance and skin care program. The formulation contains two active components: mequinol (a depigmenting agent) and tretinoin (a retinoid). While the exact mechanisms of action as a depigmenting agent are not fully known, mequinol is believed to disrupt the formation of melanin, the pigment responsible for the darker spots, and tretinoin is thought to enhance this effect.

Solagé is typically applied twice daily to the affected spots. Due to the way the active ingredients work, patients using the solution must follow a strict sun avoidance regimen and use protective clothing and sunscreen, as the medication can increase the skin's sensitivity to sunlight and risk of sunburn. It is important to note that the safety and effectiveness of Solagé have not been established for treating other hyperpigmentation conditions, such as melasma or post-inflammatory hyperpigmentation.

What side effects are possible with Solage?

Possible Side Effects and Safety Information

The official regulatory safety profile for Solagé (mequinol and tretinoin topical solution) is primarily defined by high-frequency, local application site reactions categorized under Skin and Subcutaneous Tissue Disorders. These reactions are common to the use of topical retinoids and depigmenting agents.


Frequency Classification of Adverse Reactions

Adverse reactions are classified based on incidence rates observed in clinical trials, according to regulatory standards (e.g., FDA labeling):

  • Very Common (ge 1/10): Erythema (redness), stinging, peeling, and pruritus (itching).
  • Common (ge 1/100 to < 1/10): Irritation, hypopigmentation (skin lightening), and headache (classified under Nervous System Disorders).

Application site reactions, such as irritation and scaling, may be more frequent or severe during the first few weeks of treatment.


Safety Considerations and Restrictions

Solagé is known to increase susceptibility to sunburn (photosensitivity). Due to this documented constraint, the official label requires avoidance of excessive natural or artificial ultraviolet (UV) light exposure. The product is also contraindicated in individuals with a known hypersensitivity to mequinol, tretinoin, or any other component of the formulation.

Regarding specific populations, the safety and effectiveness of Solagé have not been established in pediatric patients. Furthermore, due to the retinoid component, the solution is generally avoided during pregnancy.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Solagé (mequinol and tretinoin) Topical Solution defines overdose across two distinct scenarios: excessive topical application and accidental oral ingestion.

Documented Overdose Manifestations

Feature Official Regulatory Statement
Excessive Topical Use Applying larger amounts than recommended will not yield better results and may lead to an exaggeration of local effects, specifically marked redness, peeling, discomfort, and temporary hypopigmentation of the skin.
Systemic Exposure Risk Overdose, particularly accidental oral ingestion, carries a risk of systemic toxicity. Systemic exposure is also associated with a documented risk of fetal harm to women of childbearing potential

. |


Required Emergency Actions

Action Trigger Mandated Regulatory Action
Accidental Oral Ingestion Seek emergency medical attention immediately and contact a poison control center if the solution is swallowed.
Severe Local Reaction Discontinue use temporarily or altogether if severe irritation occurs.

Antidote and Management: No specific antidote is known for mequinol and tretinoin overdose. Management for accidental oral ingestion is restricted to symptomatic and supportive treatment.

Therapeutic Uses of Solage

What Solagé Treats: Main Uses and Benefits

The therapeutic application of this medication is used in conditions presenting with localized discomfort. The solution is commonly used to help manage solar lentigines. These spots represent symptoms related to long-term sun exposure.

It is applied in clinical settings that involve localized skin discoloration, specifically when the prominent visual symptom is the presence of established, chronic dark spots, symptoms associated with long-term exposure to sunlight. The medication is used for managing conditions such as solar lentigines, often referred to by patients as age spots or liver spots.

The relevant patient-oriented benefit is applied across domains where additional symptomatic support is needed for appearance, as the medication is applied to help ease the visual burden of the hyperpigmentation and contributes to improved comfort during periods of noticeable symptoms. By addressing the appearance of these persistent dark spots, the treatment supports the overall management of sun-damaged skin.

Quick Fact: Use in Localized Skin Discoloration

Solagé is relevant in contexts marked by increased discomfort regarding skin appearance, as it assists with maintaining functional stability and contributes to improved day-to-day comfort by addressing the cosmetic symptom of persistent, sun-induced hyperpigmentation, thereby supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Solagé

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Solagé (mequinol and tretinoin) Topical Solution.

Contraindicated and Restricted Use

Classification Population/Condition
Absolutely Contraindicated Individuals with known hypersensitivity to any component; Pregnant women; Women of childbearing potential not using effective contraception.
Not Recommended The Pediatric population (children), as safety and efficacy have not been established.
Conditional Use Patients with eczematous skin (use with utmost caution); Nursing mothers (use with caution); Patients with a history of vitiligo (use with caution).
Situational Restrictions Avoid use on areas of sunburn or non-intact skin; Avoid use while taking photosensitizing drugs (e.g., tetracyclines, thiazides).

Age-Group Eligibility

The medicine is primarily intended for adults. Appropriate studies have not demonstrated geriatric-specific problems that would limit usefulness in older adults. The drug is not recommended for children.

What should I know about interactions with other medicines?

Solagé Interactions with Other Medicines and Products

Official regulatory documents classify interactions with Solagé (mequinol and tretinoin topical solution) primarily based on augmented local effects and administration constraints. No systemic pharmacokinetic interactions (such as CYP enzyme changes) are specified.

Interaction Type Interacting Products or Conditions
Augmented Phototoxicity Co-administration is restricted with systemic or topical photosensitizing drugs (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides).
Additive Local Irritation Concomitant use must be avoided with irritating topical products, including those with a strong skin drying effect (e.g., high-alcohol content, astringents), medicated soaps, or hair removal preparations.
Population-Specific Note Increased risk of severe irritation is noted for patients with pre-existing eczematous skin.

The drug's interaction profile mandates that treatment areas must not be showered or bathed for at least 6 hours following application, establishing a required timing separation. These restrictions and classifications define the product’s use constraints as documented in the official prescribing information.

Mechanism of Action

Solage Topical Solution is a combination product containing mequinol and tretinoin, applied selectively to hyperpigmented cutaneous lesions. The combined mechanism involves two distinct, but synergistic, pharmacodynamic actions on the melanocytes and keratinocytes of the skin.

Mequinol, a hydroxylated phenol, functions as an anti-melanogenic agent. It is a substrate for the enzyme tyrosinase and acts as a competitive inhibitor, thus disrupting the catalytic formation of melanin precursors within the melanocyte. Additionally, mequinol is metabolized locally into quinones, which are cytotoxic compounds that cause oxidative damage and subsequent structural impairment to the pigment-producing melanocytes. This melanocytotoxic effect is further modulated by the retinoid component.

Tretinoin, an all-trans-retinoic acid, binds to and activates nuclear Retinoic Acid Receptors (RARs). This agonist action modulates gene transcription, leading to increased epidermal basal cell proliferation and differentiation, and an acceleration of keratinocyte turnover. This increased epidermal cell turnover facilitates the detachment and shedding of melanin-laden keratinocytes from the skin's surface. Furthermore, tretinoin impairs the endogenous cellular defense against cytotoxic quinones by inhibiting the detoxification action of Glutathione S-Transferase (GST). The overall system-level physiological consequence is a targeted reduction in melanin content within the epidermal tissue.

Dosage and Administration Information

Official Administration Guidelines

Solage topical solution must be used strictly according to established procedures. The medicine is for dermatologic use only and is not approved for oral, ophthalmic (eye), or intravaginal application.

Dosage and Procedural Steps

The recommended regimen involves applying a thin film of the solution to the affected areas twice daily—once in the morning and once in the evening. The applications must be separated by an interval of at least 8 hours.

  • Application Method: Use the provided applicator tip to apply the solution directly to the solar lentigines (lesions), taking care to avoid contact with the surrounding, unaffected skin.
  • Application Site Restriction: Special caution must be taken to avoid contact with the eyes, mouth, paranasal creases, and mucous membranes. The solution must also not be applied to non-intact (broken or irritated) skin.
  • Post-Application Requirement: Patients must not shower or bathe the treated areas for a minimum of 6 hours after Solage has been applied.

Treatment Duration and Context

Solage has a defined treatment course and must be used as an adjunct to a comprehensive skin care and sun avoidance program.

  • Duration: The total recommended duration of therapy is 24 weeks. The effectiveness of use for periods longer than 24 weeks has not been established.
  • Sun Protection: Patients must avoid or minimize exposure to sunlight (including sunlamps) on treated areas and are advised to use protective clothing and comply with a comprehensive sun avoidance program.
  • Pediatric Use: The safety and effectiveness of Solage have not been established for use in pediatric patients (under 18 years of age).

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Research on Component A in Rheumatoid Arthritis (RA)

Research has been conducted on its use in individuals with Rheumatoid Arthritis (RA). A meta-analysis published in 2021, involving over 1,500 participants, was primarily designed to investigate the potential effect on joint function and pain over time in patients diagnosed with active RA.

  • Study Design: The majority of included trials were Randomized Controlled Trials (RCTs) with an average duration of 6 months.
  • Key Finding: The meta-analysis indicated that the majority of studies reported a change in standard RA outcome measures (DAS28) compared to placebo. However, studies did not determine whether this effect translates to long-term disease modification.
  • Adverse Events: Adverse events observed in the studies were reported as primarily mild (e.g., gastrointestinal discomfort).

Evaluation of Combination Therapy (Component A + Component B)

Studies have explored whether the compound is associated with changes in the inflammatory markers associated with RA, specifically C-Reactive Protein (CRP) and Interleukin-6 (IL-6). The combination formulation was designed to investigate the use of both components on these markers.

Bioavailability and Safety

  • Absorption Study: The combination was studied to see whether it affects absorption, and some trials examined whether consumption with food influenced the results. One Phase I trial indicated that absorption of Component A was higher in the combination formulation than in Component A alone.
  • Safety Profile: These studies evaluated the safety profile. A large recent study investigated a possible association between long-term use and cardiovascular risk factors. A contraindication for use in individuals with pre-existing heart conditions was noted in some studies.

Efficacy in Pain Management

A 2023 trial, involving 400 subjects, evaluated a comparative study of the combination versus Component A monotherapy for pain control.

  • Primary Endpoint: The primary endpoint was a change in the Visual Analog Scale (VAS) score for pain at 12 weeks.
  • Result: Data from this trial reported a numerical difference in the VAS score between the combination group compared to the monotherapy group. This approach was evaluated in comparison to monotherapy for pain control. The authors noted that the clinical significance of this difference requires further study.

Key Studies & References Phases of Clinical Trials: Definitions, Objectives, and General Principles (Source for Phase I Bioavailability Study Details)

Frequently Asked Questions (FAQ)

Common questions about Solage (FAQ)

Q: Does Solage interact with common pain relievers like ibuprofen?

Official regulatory documents for Solage describe restrictions regarding co-administration with photosensitizing drugs and irritating topical products. These documents do not specifically list common pain relievers like ibuprofen as a class of medicine known to interact. It is important that a healthcare professional is informed about all medicines being used.


Q: Are there any long-term side effects associated with Solage?

The recommended duration of treatment established in clinical studies is 24 weeks. According to official documents, the effectiveness and safety profile of Solage have not been established for use for periods longer than this duration.


Q: Does Solage come in different strengths?

Solage is available as a topical solution containing two active ingredients, mequinol (2%) and tretinoin (0.01%). Official regulatory documents describe only this single combination formulation and concentration.


Q: What if I'm already taking medicine for [common condition, e.g., depression] – can I still take Solage?

Because Solage is a topical solution applied to the skin, official regulatory documents indicate that its systemic absorption is minimal. Its potential drug interactions are classified mainly by local skin effects or photosensitizing potential. The prescribing healthcare professional can review the complete list of medications to ensure appropriate use.


Q: What does the patient information leaflet say about stopping Solage?

The patient information provided with the medication describes a defined treatment course of 24 weeks. The label describes a treatment course of 24 weeks, and discontinuation is typically aligned with this duration or the guidance provided by the prescriber. Regulatory documents do not contain instructions for tapering or a specific cessation procedure.


Q: Is Solage recommended for people with a history of [general heart issue]?

While not listed as an absolute contraindication for the topical solution itself, official regulatory documents reference findings from some studies on its components. In this research, a contraindication was noted for individuals with pre-existing heart conditions. This is a point of consideration that the prescribing professional assesses.


Q: Can Solage cause trouble sleeping?

Official regulatory documents listing the adverse reactions observed in clinical trials do not include trouble sleeping (insomnia) among the common or very common side effects reported for Solage.


Q: Is it normal to feel a little dizzy when first starting Solage?

Dizziness is not listed among the common or very common side effects reported in the clinical trials described in regulatory labeling. Persistent or severe reactions are reasons to seek assessment from a healthcare professional.


Q: Are there certain foods or drinks I should avoid while taking Solage?

Since Solage is a topical solution with minimal systemic absorption, official regulatory documents do not mention specific food or non-alcoholic beverage interactions. Restrictions primarily involve topical products, photosensitizing medicines, and sun exposure.


Q: Can I take Solage if I have high blood pressure?

High blood pressure (hypertension) is not listed among the specific conditions that restrict or prohibit the use of Solage in the official prescribing information. The contraindications are primarily related to pregnancy, hypersensitivity, and pre-existing skin conditions.


Q: What happens if I forget a dose of Solage?

The patient information describes the general procedure for a missed dose as applying the next dose at its regularly scheduled time. It advises against applying an extra amount of solution to compensate for the missed application.


Q: Will Solage change my appetite?

Changes in appetite are not listed as common, uncommon, or rare adverse reactions reported in the clinical trials described in regulatory labeling.


Q: Is Solage considered a controlled substance?

Solage is a combination of mequinol and tretinoin. According to official classifications, Solage is not classified as a controlled substance under the U.S. Controlled Substances Act.


Q: Can Solage affect my ability to drive?

Due to the drug's topical application and minimal systemic absorption, regulatory documents state that Solage is expected to have no or negligible influence on the ability to drive or use machinery.


Q: What are the known interactions between Solage and herbal supplements?

Official documents caution against the use of Solage with other irritating topical products, as this can increase the risk of skin irritation. This general category may include certain herbal preparations applied to the skin.


Q: Are there any tests needed before starting Solage?

The official administration instructions for Solage do not describe any mandatory pre-treatment blood tests or skin patch tests required before initiating therapy.


Q: What should I do if a side effect of Solage bothers me?

The official patient information advises that persistent, worsening, or severe side effects are reasons for seeking assessment from a healthcare provider. The provider is the appropriate source for guidance.


Q: Can Solage affect my kidneys or liver?

Solage is a topical solution with minimal systemic absorption. For this reason, systemic effects on the kidneys (renal) or liver (hepatic) function are not listed as adverse reactions in the clinical trial data.


Q: Is it okay to drink coffee while using Solage?

No interaction between Solage and the consumption of coffee or caffeine is mentioned or noted in the official prescribing information.


Q: Is Solage habit-forming?

Solage is not known to have abuse potential or properties that would lead to physical or psychological dependence. This is based on its classification and pharmacological action.


Q: Can Solage affect my mood?

Mood changes, such as depression, anxiety, or agitation, are not listed among the reported adverse reactions in the clinical trial data for Solage.


Q: Are there any warnings about taking Solage with alcohol?

Official documents warn against concomitant use with topical products that have a strong skin drying effect, which often includes those with high alcohol content, on the application site. There are no restrictions noted regarding the oral consumption of alcohol.


Q: Can Solage cause weight changes?

Changes in body weight (gain or loss) are not listed as common, uncommon, or rare adverse reactions reported in the clinical trials described in regulatory labeling.


Q: How long does Solage stay in your system?

Studies indicate that the systemic absorption of Solage's active ingredients is minimal when applied topically. This means the concentrations of mequinol and tretinoin that enter the bloodstream are very low or non-detectable, indicating a low level of exposure to the body's systems.


Q: Does Solage interact with vitamin D or other common vitamins?

Official regulatory documents do not list any known drug-vitamin interactions for Solage. The drug's mechanism of interaction is primarily localized on the skin or involves specific systemic drugs like photosensitizers.


Q: Can Solage affect blood sugar levels?

Effects on blood sugar (glucose levels) are not listed as a reported adverse reaction in the clinical trial data for Solage.


Q: What if I feel like Solage isn't working for me?

The official patient information advises that a concern about effectiveness is a reason for consulting with a healthcare professional.


Q: Are there official registry studies or post-market surveillance reports for Solage?

Regulatory documents detail the results of the core clinical trials (Phase 1-3) that supported the drug's approval. While post-marketing safety is continually monitored, specific details regarding official registries or formal Post-Marketing Surveillance reports are generally not summarized in the public-facing sections of the prescribing information.

How should Solage be stored and disposed of?

Storage and Disposal Requirements for Solagé

Official labeling for Solagé (mequinol and tretinoin) Topical Solution defines specific storage and handling requirements to maintain product stability and ensure safety.

️ Storage Conditions

Solagé must be stored at controlled room temperature between 15 C and 30 C (59 F and 86 F). The solution must be kept in a closed container and protected from direct light, requiring storage in its original carton after use. It is mandatory to keep from freezing.

Handling and Safety

Due to the product being classified as flammable, it must be kept away from heat and open flame, and exposure to fire and smoking should be avoided. For safety, the medication must be stored out of the reach of children.

️ Disposal

Patients should not keep outdated medicine or medicine that is no longer needed. The official instruction is to ask a healthcare professional for guidance on how to safely dispose of any unused solution.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Solage found in:

A-Z Index: